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Abstract
Background: A high incidence of decreased bone mineral density (BMD) has been associated with
HIV infection. Normal skeletal homeostasis is controlled, at least in part, by the maturation and
activity of mature osteoblasts. Previous studies by our group have demonstrated the ability of HIV
proteins to perturb osteoblast function, and the degree of osteogenesis in differentiating
mesenchymal stem cells (MSCs). This study attempts to further dissect the dynamics of this effect.
Methods:  MSCs were cultured under both osteogenic (cultured in commercially available
differentiation media) and quiescent (cultured in basal medium) conditions. Both cell populations
were exposed to HIV p55-gag and HIV rev (100 ng/ml). Time points were taken at 3, 6, 9, and 15
days for osteogenic conditions, while quiescent cells were treated for 1 week. Cell function
(alkaline phosphatase [ALP] activity, calcium deposition, and lipid levels) and the activity of the key
MSC transcription factors, RUNX-2 and PPARgamma were determined post-exposure. Also, in
cells cultured in differentiating conditions, cellular levels of connective tissue growth factor (CTGF)
were analysed using whole cell ELISA, while BMP-2 secretion was also examined.
Results: In differentiating MSCs, exposure to HIV proteins caused significant changes in both the
timing and magnitude of key osteogenic events and signals. Treatment with REV increased the
overall rate of mineralization, and induced earlier increases in CTGF levels, RUNX-2 activity and
BMP-2 secretion, than those observed in the normal course of differntiation. In contrast, p55-gag
reduced the overall level of osteogenesis, and reduced BMP-2 secretion, RUNX-2 activity, CTGF
levels and ALP activity at many of the timepoints examined. Finally, in cells cultured in basal
conditions, treatment with HIV proteins did not in and of itself induce a significant degree of
differentiation over the time period examined.
Conclusion: These data demonstrate that the effect of HIV proteins on bone is dependent on the
differentiation status of the cells that they are in contact with. The effect on bone cell signalling
provides insights into the mechanism of HIV induced decreases in bone mineral density.
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Background
Osteoporosis is characterised by a severe loss of bone
mass with consequent reduction in bone strength, leading
to an increased fracture risk. Osteopenia is the lesser
reduction of bone mass which precedes osteoporosis [1].
Recent studies have suggested an association between
bone abnormailites, including osteoporosis, ostepenia,
and osteolysis, and HIV infection [1,2]. However, the
molecular and cellular mechanisms underpinning these
HIV associated changes in bone biology remain unclear,
with some, but by no means all, studies linking these
abnormalities with the use of potent antiretroviral medi-
cations [3-11].
The balance between osetoclast mediated bone resorption
and osteoblast mediated bone deposition is the essential
feature of homeostatic bone remodelling. This process
allows the regulation of skeletal growth and repair, and
the maintenance of skeletal integrity. Osteoblasts (OB)
and Osteoclasts (OC) are derived from different cell line-
ages, with OBs being formed by the differentiation of mes-
enchymal stem cell (MSC) precursors in the bone
marrow, and OCs dervived from hematopoietic cells and
are distantly related to other cell types such as monocytes
and machrophages. Just as the bone producing and
degrading functions of OBs and OCs balance each other,
a complex arrangement of intercellular signalling between
OBs and OCs allow their maturation, relative number,
and activity to be regulated [9-13]. Vital to this intercellu-
lar signalling system are the bone morphogenic proteins,
BMP2-9, which regulate osteoblast function and develop-
ment; In the case of BMP2 and BMP7, an activity that is
mediated via induction of the activation and expression of
the transcription factor RUNX-2 [14-17].
Mesenchymal stem cells (MSC) are bone marrow derived
pluripotent cells which differentiate into several mesen-
chymal cell types, including OBs and adipocytes (AC)
[18]. Their differentiation is a tightly regulated and, as of
yet, not fully elucidated process [19] However its is
believed that the balance between transcription factors
RUNX-2 (also called Cbfa1) and peroxisome proliferator
activated receptor (PPARγ); plays a crucial role in control-
ling MSC development [19], with RUNX-2 driving a pro-
osteogenic phenotype and PPARγ a pro-adipogenic one,
Alterations in the ratio of OBs to ACs generated from
MSCs have been clinically linked to decreased bone mass,
with an increase in bone marrow AC content observed in
both osteoporosis and osteopenia [19,20], while other
conditions which lead to bone loss, such as treatment
with glucocorticoids, have also been shown to increase
the number of bone marrow ACs [19,21].
The widely accepted model of the progression of osteo-
genesis is that the differentiating mesenchymal stem cell
proceeds through a number of functional stages, namely
proliferation, matrix maturation, and mineralization.
These stages are indicative of phenotypical transition of
the pluripotent MSC to a committed osteoprogenitor, pre-
osteoblast, early osteoblast and finally a mature osteob-
last [22,23].
Molecules associated with induction of osteogenesis
include connective tissue growth factor (CTGF), a 38-kDA
protein expressed in a number of cell types including
fibroblasts and MSCs. CTGF is a member of a family of
cysteine rich proteins, other members of which are associ-
ated with a wide variety of biological processes such as
embryonic development and repair [22]. In MSC differen-
tiation, increased CTGF expression is associated with the
early stages of osteogenesis (proliferation, matrix matura-
tion), preceeding such other later osteogenic markers such
as alkaline phosphatase activity and mineralization
[22,23].
Previous studies by our group have demonstrated that
treatment with the HIV proteins p55-gag and gp120 could
impair osteoblast function, reduce secreted levels of BMP-
2, osteocalcin and RANK-L, and reduce RUNX-2 expres-
sion and activity. In addition, our group has also previ-
ously published data showing that HIV-p55 and REV
decrease and increase the degree of MSC osteogenesis
respectively [24].
Herein we have extended our investigation into the effects
of HIV proteins on MSC osteogenesis. Initially the effect
of varying concentrations of an array of HIV1 proteins
MSC osteogenesis was examined. Following that we
examined the osteogenic markers of alkaline phosphatase
activity and calcium deposition, as well as quantifying cel-
lular levels of CTGF, secreted BMP-2 and RUNX-2 tran-
scription factor activity over the time course of
osteogenesis in the presence and absence of p55-gag and
REV. Furthermore, to determine whether HIV proteins
themselves can influence MSC differentiation, we treated
non differentiating MSCs with REV and p55-gag and
examined levels of calcium deposition, alkaline phos-
phatase activity, lipid levels as well as examining RUNX-2
and PPARγ transcription factor activity. The data pre-
sented herein demonstrates that although HIV p55-gag
and REV do not in and of themselves induce MSC differ-
entiation, they alter the timing and magnitude of impor-
tant osteogenic signals and events throughout the natural
history of MSC differentiation.
Methods
Cell Culture
A commercially available human Mesenchymal Stem Cell
(derived from human bone marrow withdrawn from the
posterior iliac crest of the pelvic bone of normal volun-BMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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teers) line was obtained from LONZA, UK, and routinely
cultured at 37°C, 5% CO2 in Mesenchymal Stem Cell
growth media. Cells were differentiated by culturing in
Osteoblast Differentiation media (LONZA UK) for 15
days. Cells were used between passage 3–6.
Cells were treated with varying concentrations of (10 ng/
ml–100 ng/ml) HIV rev, p55-gag, TAT and gp120 pro-
teins. Both undifferentiated  and differentiating  cells were
treated with HIV proteins. REV and P55-gag have been
previously shown by our group to affect osteogenesis over
a 21 day time course at 100 ng/ml, a concentration previ-
ously determined to be representative of in vivo levels of
HIV gp120 in untreated patients [11,24].
Viral proteins were obtained from the NIH aids reagent
program [25]; HIV-1 Rev (Wild Type;) was obtained
through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH: HIV-1 Rev (Wild
Type) from Dr. David Rekosh, Dr. Marie-Louise Hammar-
skjöld and Mr. Michael Orsini. HIV-1IIIB p55 Gag; was
obtained through the NIH AIDS Research and Refer-
enceReagent Program, Division of AIDS, NIAID, NIH:
HIV-1IIIB p55 Gag. HIV-1 Tat Protein The following reagent
was obtained through the NIH AIDS Research and Refer-
ence Reagent Program, Division of AIDS, NIAID, NIH:
HIV-1 Tat protein from Dr. John Brady and DAIDS,
NIAID. HIV-1 CN54 gp120. The following reagent was
obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1
CN54 gp120 from DAIDS, NIAID
Alkaline phosphtase staining
Cells were cultured in a 96 well plate, and treated as
described above. Cells were then washed in PBS and fixed
with 100 µl ice cold 1:1 Ethanol:Acetone for 10 mins.
After cell number determination (see below), cells were
washed several times in PBS to remove any remaining
stain, and allowed to air dry. SigmaFAST BCIP/NBT solu-
tion was prepared as per manufacturers instructions, and
100 ul of stain solution added to each well. The plate was
then incubated for 30 mins at 37°C. Unstained, similarly
treated wells, were also included as blanks. Following
incubation, the remaining substrate solution was
removed, the wells washed 3 times with 100 ul PBS, and
allowed to air dry. The plate was then scanned at 300 dpi
using a standard flatbed scanner.
The degree of staining was quantitated spectrophotmetri-
cally; 100 ul 1%CPC was added to each well and the
plates incubated with agitation for 30 mins (100 rpm).
The plates were then read at 560 nm with a correction
wavelength of 700 nm.
Calcium Deposition
Cells were cultured in a 96 well plate, and treated as
described above. Cells were then washed in PBS and fixed
with 100 µl ice cold methanol for 10 mins. After cell
number determination (see below), cells were washed
several times in PBS to remove any remaining stain, and
allowed to air dry. 100 ul of 40 mM alizarin red (pH 4)
solution was added to each well. The plate was then incu-
bated for 10 mins at room temperature. Unstained, simi-
larly treated wells were also included as blanks. Following
incubation, the remaining stain solution was removed,
the wells washed 3 times with 100 ul PBS, and allowed to
air dry. The plate was then scanned at 300 dpi using a
standard flatbed scanner.
The degree of staining was quantitated spectrophotomet-
rically; 100 ul 1%CPC was added to each well and the
plates incubated with agitation for 30 mins (100 rpm).
The plates were then read at 557 nm with a correction
wavelength of 700 nm and alizarin red concentration
determined using a standard curve of concentration vs.
OD557 nm. Data was normalised to cell number per well.
Lipid Staining
Lipid levels were assessed using a quantitative oil-red-o
protocol adapted for use in a 96-well plate format. Briefly,
undifferentiated MSCs were cultured and treated as
described above. Cells were then washed in PBS and fixed
with 100 µl formalin (8%) for 10 mins. After cell number
determination (see below), cells were washed several
times in PBS to remove any remaining stain, and allowed
to air dry. A stock solution of Oil Red-O (sigma) was pre-
pared (5 mg/ml 60% isopropanol). This was used to pre-
pare a working solution 3.3 mg/ml, which was then
filtered. 100 µl of this solution was added to each well,
and left to stain for 15 mins. Post staining cells were
washed (1 wash 60% isopropanol, 2 wash PBS), and
allowed to air dry before being de-stained with 80 µl 1%
CPC (10 mins, agitation [100 rpm]). Again unstained
wells containing similarly treated cells were included as
blanks for each treatment. Each plate was read at 530 nm,
with a reference wavelength of 700 nm, and Oil Red-o
concentration determined using a standard curve of con-
centration vs. OD530. Data was normalised to cell number
per well. In undifferentiated MSCs, levels of lipid staining
were modest, the staining being visible to the naked eye,
but differences being undeterminable.
Cell Number Determination
After fixation cells were washed twice with PBS and
allowed to air dry, before being stained with ponceau red
(100 µl per well, 10 mins). Unstained wells containing
similarly treated cells were included as blanks for each
treatment. The cells were then washed twice with 200 µl
PBS per well to remove excess stain, air dried andBMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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destained (100 µl PBS per well, 10 mins, agitation [100
rpm]). The plate was then read at 540 nm, with a reference
wavelength of 700 nm, and cell number per well deter-
mined using a standard curve of cell no vs. OD540.
Unstained wells containing similarly treated cells were
included as blanks for each treatment.
For differentiation experiments, as increased production
of proteinaceous extracellular matrix made cell number
determination using protein staining inaccurate, DNA
staining with 1% methylene green (dH2O) was used. Cells
were stained/destained in a similar manner to ponceau
red, and dye extracted was read at 600 nm, with cell
number per well determined using an appropriate stand-
Validation of whole cell elisa protocol for ICAM, and CTGF Figure 1
Validation of whole cell elisa protocol for ICAM, and CTGF. Fig. S1 A, B; standard curves for cell # vs. OD for ponceau 
red (protein) and methylene green (DNA) respectively. Fig. S1 C, D; time and dose response curves for ICAM detected by 
whole cell elisa vs. TNFα. Fig. S1E; CTGF levels as measured by whole cell ELISA vs. DEX and TGF-β concentration. Fig. S1A, 
B; data is presented as zeroed OD ± SEM. Fig. S1. C, D, E, F; data is presented as fold change relative to untreated control ± 
SEM. All data is the mean of several independent experiments. (Significance determined at; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005.)BMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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ard curve. (standard curves for both ponceau red and
methylene green are shown in Fig. 1a and 1b).
Whole Cell ELISA
MSCs were cultured in 96 well plates and treated as
described above. Following treatment cells were washed
with PBS and fixed with 100 ul ice cold methanol per well.
Cell number was determined as described above.
Following determination of cell number the cells were,
soulbilised with 1% tritonX/PBS for 5 mins, and blocked
in 100 ul PBS containing 10% BSA for 30 mins. The cells
were then treated with 100 ul of appropriate primary anti-
body dilution [rabbit anti-CTGF (santa cruz): 1/200,
mouse anti-ICAM 1/200 (santa cruz); all dilutions in PBS/
10% BSA] and incubated for one hour at room tempera-
ture. Following incubation wells were washed three times
with PBS containing 0.05% tween, and incubated with
appropriate concentrations of horse radish peroxidase
(HRP) labeled secondary antibodies [anti-rabbit HRP
(sigma): 1/300, anti-mouse HRP (sigma): 1/250; all dilu-
tions in PBS/10%BSA]. Wells incubated with secondary
antibody were included for each treatment as a control for
non-specific binding and to act as blanks.
Following incubation with secondary antibody, the wells
were washed four times PBS containing 0.05% tween, and
allowed to air dry. SigmaFAST OPD was prepared as per
the manufacturers instructions, and 100 ul of the solution
added to all wells. The plate was then incubated at room
temperature in the dark for 15 mins. After incubation the
reaction was stopped by the addition of 50 ul 0.1 M acetic
acid, and the plates read on a spectrometer at 450 nm, cor-
rection wavelength 600 nm. OD values for each well were
zeroed by subtraction of the value of the appropriate sec-
ondary-only control, and the zeroed value normalized to
cell number.
The optimum concentraction of primary/secondary anti-
bodies were determined using concentration gradients.
The assay was also validated for each ICAM, and CTGF
antibodies using an appropriate positive control treat-
ment, TNFα – ICAM [26], and dexamethasone/TGFβ –
CTGF [27,28] (Fig. 1c, d, e, respectively).
BMP-2 ELISA
Post treatment cell supernatants were collected, centri-
fuged at 1000 rpm/5 min to remove cellular debris, aliq-
uoted, and stored at -80°C. A commercially available
ELISA kit was then used to determine the concentration of
BMP-2 (R&D systems, USA). The assay was carried out
and analysed as per manufacturer's instructions.
Transcription Factor Activity Assays
RUNX-2 and PPARγ transcription factor activity was deter-
mined using a commercial TransAM™ assay as per manu-
facturers instructions (Active Motif, Belgium). TransAM
Kits are highly sensitive ELISA based assays that enable the
detection of activated transcription factors in mammalian
tissue and cell culture extracts. TransAM Kits are easy-to-
use and up to 100-fold more sensitive than gel-shift
assays. The kits comprise a 96 well plate on which a con-
sensus sequence for the transcription factor in question
has been imobilised (RUNX-2, 5'-AACCACA-3'; PPARγ,
5'-AACTAGGTCAAAGGTCA-3' [PPRE]). Nuclear extracts
are then added to the plates and allowed to bind. Positive
controls were also included, namely nuclear extracts from
cell lines tranfected with constructs over-expressing
RUNX-2/PPARγ. Wild type and mutated consensus
sequence could also be included to monitor the specificity
of the assay. Protein bound to the consensus sequence
was then treated with specific primary antibody, which
was then be detected using HRP labeled secondary anti-
body and a colourimetric substrate. The assay was read at
450 nm, and readings were normalized to protein concen-
tration.
Statistical Analysis
Statistical analysis was performed using students unpaired
t-test, with significance determined at *p ≤ 0.05, **p ≤
0.01, and ***p ≤ 0.005 relative to untreated control, and
^p ≤ 0.05, ^^p ≤ 0.01, and ^^^p ≤ 0.00 relative to differ-
entiated control.
Results
Treatment with HIV proteins p55-gag and REV 
dysregulates MSC osteogenic differentiation
Cells were cultured in ostegenic conditions in a 96-well
plate format for 15 days in the presence of varying concen-
trations (10 ng/ml, 50 ng/ml, 100 ng/ml) of HIV-1 pro-
teins gp120, p55-gag REV and TAT. Untreated,
differentiated cells were included as controls. After 15
days the cells were harvested, fixed and stained for cal-
cium deposition (alizarin red) (Fig. 2A) and alkaline
phosphatase activity (BCIP/NIB) (Fig. 2B), known mark-
ers of osteogenic differentiation. Stained cells were photo-
graphed and the dyes were extracted and quantified
spectrophotometrically. Only p55-gag and REV were seen
to significantly alter either alkaline phosphatase activity
and calcium deposition relative to differentiated controls;
all concentrations of REV significantly increased calcium
deposition (> 30% relative to differentiated control, p ≤
0.05), while the higher concentrations were also seen to
alter alkaline phosphatase activity. All concentrations of
p55-gag were seen to significantly reduce alkaline phos-
phatase activity (> 10% relative to differentiated control,
p ≤ 0.05), while only treatment with 100 ng/ml p55-gag
was seen to reduce calcium deposition significantly (22.4BMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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± 7.1% relative to differentiated control, p ≤ 0.05). TAT
proteins also induced increases in both calcium deposi-
tion and alkaline phosphatase activity at most of the con-
centrations examined, however. The effect of
combinations of the proteins (all used at 100 ng/ml) on
MSC osteogenesis was also examined; combination of
p55-gag or TAT with REV did not attenuate the increase in
calcium deposition observed with REV alone (Fig. 2C),
while none of the other combinations of proteins signifi-
cantly altered either alkaline phosphatase or calcium dep-
osition relative to the differentiated control (Fig. 2C, D).
To more closely examine the individual impact of the REV
and p55-gag proteins on the osteogenic process, MSCs
were cultured in osteogenic media for 15 days in the pres-
ence of either100 ng/ml p55-gag or REV, and time points
taken at 3, 6, 9 and 15 days. Again cells were fixed, and
stained for ALP activity (Fig. 3A, B) and calcium deposi-
tion (Fig. 3C, D).
ALP showed maximum induction in the differentiated
control cells at 9 days, with an increase of 167 ± 32% (p ≤
0.001) relative to undifferentiated control. The degree of
Effect of varying concentrations and combnations of HIV1 proteins on MSC osteogenesis Figure 2
Effect of varying concentrations and combnations of HIV1 proteins on MSC osteogenesis. MSCs were cultured in 
a 96-well plate format and induced to differentiate in the presence and absence of 10–100 ng/ml of HIV REV, gp120, p55-gag, 
and TAT. Untreated, differentiated cells were included as controls. Cells were harvested at 15 days post induction of differen-
tiation, fixed and stained for either calcium deposition (alizarin red) or alkaline phosphatase (BCIP/NBT). Plates were first pho-
tographed, then the stain extracted, and the degree of staining quantified spectrophotometrically and normalised to cell 
number. Fig 2A; calcium staining normalised to cell number for diferentiating MSCs (diff con), and differentiating MSCs exposed 
to 10–100 ng/ml HIV gp120, p55-gag, REV and TAT proteins, data expressed as percentage of untreated control ± SEM. Fig 2B; 
ALP staining normalised to cell number, for diferentiating MSCs (diff con), and differentiating MSCs exposed to 10–100 ng/ml 
HIV gp120, p55-gag, REV and TAT. proteins, data expressed as percentage of untreated control ± SEM. Differentiating MSCs 
were also incubated with various combinations of HIV1 proteins (all proteins at 100 ng/ml), and there affects on calcium depo-
sition and alkaline phosphatase staining assayed and quantified as described. Fig 2C; Fig 2A; calcium staining normalised to cell 
number for differentiating MSCs (diff control), and differentiating MSCs exposed to either 100 ng/ml REV/p55, 100 ng/ml p55/
REV/TAT, 100 ng/ml p55/REV/TAT/gp120, 100 ng/ml p55/gp120, or 100 ng/ml REV/TAT proteins, data expressed as percent-
age of untreated control ± SEM. Fig 2D; ALP staining normalised to cell number, for differentiating MSCs (diff con), and differ-
entiating MSCs exposed to either 100 ng/ml REV/p55, 100 ng/ml p55/REV/TAT, 100 ng/ml p55/REV/TAT/gp120, 100 ng/ml p55/
gp120, or 100 ng/ml REV/TAT proteins, data expressed as percentage of untreated control ± SEM. All data is the mean of sev-
eral independent experiments. (Significance determined at; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005 relative to undifferentiated control, 
^p ≤ 0.05, ^^p ≤ 0.01, ^^^p ≤ 0.005 relative to differentiated control).BMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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increase in ALP staining (70 ± 18.9%, p ≤, n = 6) in cells
treated with p55-gag was significantly lower than the dif-
ferentiated control (p ≤ 0.05, n = 6), while in cells treated
with REV there was no significant difference in the degree
of induction. A similar pattern was observed at 15 days,
albeit with a lower overall level of ALP induction in the
differentiated control (74 ± 18.9% relative to untreated
control, p ≤ 0.001, n = 6).
The maximum increase in calcium deposition was
observed at 15 days; with an increase of 173 ± 73% (p ≤
0.05, n = 6) in untreated, differentiated cells. Treatment
with p55-gag significantly reduced the degree of calcium
deposition relative to differentiated control, while REV
increased it (p ≤ 0.05 relative to differentiated control, n =
6); with increases of 82.4% ± 10% and 430 ± 71% relative
to untreated control respectively (p ≤ 0.001, n = 6).
HIV proteins induce changes in calcium deposition, 
alkaline phosphatase activity, and lipid levels in non-
differentiating MSCs
Having demonstrated that the HIV proteins p55-gag and
REV could disregulate the osteogenic differentiation proc-
ess in MSCs, we attempted to determine if these proteins,
in and of themselves, could induce any degree of differen-
tiation.
Cells were cultured for 7 days in the presence of 100 ng/
ml p55-gag and REV. Untreated cells were included as
controls. Cells were harvested, fixed, and stained for cal-
cium deposition (alizarin red), for ALP activity (BCIP/
NIB), and lipid levels (oil red-o) (Fig. 4). Stained cells
Effect of HIV1 p55-gag and REV on MSC osteogenesis Figure 3
Effect of HIV1 p55-gag and REV on MSC osteogene-
sis. MSCs were cultured in a 96-well plate format and 
induced to differentiate in the presence and absence of HIV 
REV and p55-gag. Untreated, undifferentiated cells were 
included as controls. Cells were harvested at 3, 6, 9 and 15 
days post induction of differentiation, fixed and stained for 
either calcium deposition (alizarin red) or alkaline phos-
phatase (BCIP/NBT). Plates were first photographed, then 
the stain extracted, and the degree of staining quantified 
spectrophotometrically and normalised to cell number. Fig 
3a; alkaline phosphatase (ALP) staining in untreated MSCs 
(con), diferentiating MSCs (cd), and differentiating MSCs 
exposed to HIV p55-gag and REV proteins. Fig 3b; ALP stain-
ing normalised to cell number, data expressed as percentage 
of untreated control ± SEM. Fig 3c; calcium staining in 
untreated MSCs (con), diferentiating MSCs (cd), and differen-
tiating MSCs exposed to HIV p55-gag and REV proteins. Fig 
3d; calcium staining normalised to cell number, data 
expressed as percentage of untreated control ± SEM. All data 
is the mean of several independent experiments. (Significance 
determined at; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005 relative to 
undifferentiated control, ^p ≤ 0.05, ^^p ≤ 0.01, ^^^p ≤ 0.005 rel-
ative to differentiated control).
Effect of hiv proteins on non differentiating MSCs Figure 4
Effect of hiv proteins on non differentiating MSCs. 
MSCs were cultured in 96-well plates in the presence of 100 
ng/ml HIV p55-gag and REV for 7 days. Untreated cells were 
included as controls. Cells were harvested and the stained 
for alkaline phosphatase, calcium deposition, and lipid accu-
mulation (Fig. 4). Following staining dyes were extracted, the 
degree of staining quantified spectrophotometrically and nor-
malised to cell number. Data expressed percentage of 
untreated control ± SEM. All data is the mean of several 
independent experiments. (Significance determined at; *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.005)BMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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were photographed and the dye was extracted and quanti-
fied spectrophotometrically.f
REV increased calcium deposition slightly (12.2 ± 5.4%, p
≤ 0.05, n = 6), while both REV and p55-gag induced
increases in alkaline phosphatase staining (29.1 ± 8.4%
and 19.3 ± 8.9% respectively, p ≤ 0.05, n = 6). Both pro-
teins significantly reduced the levels of lipid staining, with
p55-gag induced a decrease of 46.6 ± 14% and REV and
decrease of 48.4 ± 8.6% respectively (p ≤ 0.01, n = 6).
P55-gag and REV alter BMP-2 secretion, cellular levels of 
CTGF, and RUNX-2 activity in differentiating MSCs
Having determined that p55-gag and REV could disregu-
late the osteogenic process in MSCs, we examined the
effect of treatment with HIV proteins on the levels and
activity of three molecules important in the process of
osteogenesis in MSCs, (BMP-2, CTGF and RUNX-2), over
the course of differentiation.
Cells were cultured in osteogenic media for 15 days in the
presence of 100 ng/ml p55-gag and REV. Both untreated
and undifferentiated cells were included as controls. Cells
were harvested at 3, 6, 9 and 15 days; cells were fixed and
cellular levels of CTGF determined using whole cell elisa
(Fig. 5A), media fractions were harvested and analysed for
BMP-2 levels (Fig. 5B), while nuclear extracts also were
prepared and analysed for RUNX-2 activity (Fig 5C).
CTGF levels (Fig. 5A) in the differentiated control show a
significant increase relative to undifferentiated control at
day 3 and day 6 (13.2 ± .3% and 41.7 ± 5% respectively;
p ≤ 0.001, n = 6). In contrast, levels in cells treated with
REV were significantly higher than differentiated control
in day 3, and 15, and lower in day 6 (p ≤ 0.05 relative to
differentiated control, n = 6). REV also induces a small but
significant increase relative to undifferentiated control at
day 9 (13.7 ± .47%, p ≤ 0.05). Levels in cells treated with
p55-gag are significantly lower than the differentiated
control at day 6, while there is a small but significant
decrease relative to undifferentiated control at day 9 (16.8
± 5%, p ≤ 0.05, n = 6).
Levels of BMP-2 (Fig. 5B) secretion were altered in differ-
entiated controls at days 9 and 15 with increases of 125.1
± 2.1% and 282.7 ± 30% relative to undifferentiated con-
trol respectively (p ≤ 0.05, n = 4). In contrast the level of
BMP-2 secretion in cells treated with REV increased at day
3, (91.2 ± 14.2% relative to undifferentiated control, p ≤
0.05, n = 4), which was also significantly greater than the
differentiated control (p ≤ 0.05), and decreased at day 15
(28 ± 9.6% relative to undifferentiated control) which was
also significantly lower than the differentiated control (p
≤ 0.05, n = 4). Levels of BMP-2 secretion in cells treated
with p55-gag were significantly lower than undifferenti-
ated control at day 3 (p ≤ 0.05, n = 3), and significantly
lower than levels of the differentiated control at days 9
and 15 (p ≤ 0.01 and p ≤ 0.05 respectively, n = 4).
The levels of RUNX-2 activity (Fig. 5C) in untreated differ-
entiating cells did not alter significantly relative to undif-
ferentiated control until day 9, when a significant increase
of 39 ± 9% is observed (p ≤ 0.05, n = 3). By day 15 the lev-
els of RUNX-2 in differentiating cells activity dropped sig-
nificantly relative to undifferentiated control by 32 ± 11%
(p ≤ 0.05, n = 3). Differentiating cells treated with REV
showed earlier and significantly greater increases in activa-
tion (day 6; 78 ± 0.4%. day 9; 48 ± 0.8%: n = 3, p ≤ 0.05
relative to undifferentiated control), and did not exhibit
the drop in activity at day 15 shown by the differentiated
control. However levels at day 3 are significantly lower
than those of both the control and differentiated control
cells. Treatment with p55-gag significantly reduces levels
of RUNX-2 activity relative to differentiated control at all
time points.
HIV proteins induce changes in levels of RUNX-2 and 
PPARγ activity in non-differentiating MSCs
Having shown that both p55-gag and REV can induce
changes in the levels of osteogenic and adipogenic makers
in non-differentiating MSCs, we examined their effect on
the transcription factors PPARγ and RUNX-2, which are
know to drive an adipogenic or osteogenic phenotype
respectively.
Cells were treated with 100 ng/ml p55-gag and REV for 7
days. Untreated cells were included as controls. Nuclear
extracts were prepared and analysed for RUNX-2 and
PPARγ activity (Fig. 6).
REV induced an increase in the activity of RUNX-2 of 23.3
± 8% (p ≤ 0.05, n = 4). In addition REV also induced a sig-
nificant increase in PPARγ activity (151 ± 21.8%, p ≤
0.005, n = 4) (Fig. 6A). Although p55-gag induced smaller
increases in the levels of activity of both proteins, these
increases were not significant.
Discussion
Previous studies by our groups have indicated that the
HIV1 gp120 and p55-gag proteins could regulate osteob-
last function. In this study we further examined the effect
of exposure to HIV proteins on MSC ostegenic differenti-
ation over a 15 day time course. Initial experiments exam-
ined the effects of an array of HIV-1 proteins; the capsid
protein p55-gag, the coat protein gp120, and the proteins
transcriptional regulatory proteins REV and TAT. These
experiments demonstrated that REV and p55-gag, alone
and in combination, could significantly alter MSC osteo-
genesis. To further determine the effect of REV and p55-
gag on the key signalling events involved in osteogeneis,BMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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HIV1 proteins alter RUNX-2 activity, BMP-2 secretion and cellular levels of CTGF in differentiating MSCs Figure 5
HIV1 proteins alter RUNX-2 activity, BMP-2 secretion and cellular levels of CTGF in differentiating MSCs. 
MSCs were cultured in a 96-well plate format and induced to differentiate in the presence and absence of 100 ng/ml of HIV 
REV and p55-gag. Untreated, undifferentiated cells were included as controls. Cells were harvested at 3, 6, 9 and 15 days post 
induction of differentiation; whole cell ELISA was performed for CTGF (Fig. 5A), media fractions were analysed for BMP-2 lev-
els (Fig. 5B), while nuclear extracts were assessed for RUNX-2 activity (Fig. 5C), Data expressed percentage of untreated con-
trol ± SEM (A, C,), or pg BMP-2 per ml-1/µg cellular protein extracted (B) ± SEM. All data is the mean of several independent 
experiments. (Significance determined at; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005 relative to undifferentiated control, ^p ≤ 0.05, ^^p ≤ 
0.01, ^^^p ≤ 0.005 relative to differentiated control).BMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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we examined the functional markers of ALP activity and
calcium deposition, and also examined RUNX-2 activity,
BMP-2 secretion, and total cellular levels of CTGF.
The generally accepted model of the progression of osteo-
genesis is as follows, there is an early proliferative stage
(day 0–4) followed by a period of matrix maturation day
(3–14), and finally the mineralization stage (day 13–15),
indicating the transition of the pluripotent MSC to a com-
mitted osteoprogenitor, preosteoblast, early osteoblast
and finally a mature osteoblast [23,23]. We examined a
number of important signalling proteins and osteoblastic
markers over the course of differentiation (ALP, calcium
deposition, BMP-2, RUNX-2, CTGF). Our findings in un
HIV treated differentiating cells, correlate with the
accepted model of osteogenic differentiation; in our
model (see Fig. 6), an increase in CTGF production at day
3–6 was consistent with the onset of matrix maturation in
the preosteoblast, while increases in BMP-2 secretion,
RUNX-2 activity and ALP activity between day 6–9 was
indicative of the preosteoblast stage, with the final
increase in mineralization observed at day 15 as the cell
became a mature osteoblast. Interestingly, we demon-
strated a decrease in RUNX-2 activity at day 15, an obser-
vation which is in keeping with findings that suggest that
although RUNX-2 expression is essential for osteoblast
development and function, in the maturing cell type its
overexpression blocks terminal differentiation and
increases bone resorption [29].
Treatment with both p55-gag and REV altered both the
final degree of differentiation and the levels of many of
the parameters examined over the 15 day timecourse.
P55-gag significantly reduced the degree of osteogenesis
(as measured by ALP levels and calcium staining) at day
15. Reductions in RUNX-2 activity relative to differenti-
ated control was also observed at all time points, and the
secretion of BMP-2 is also reduced relative to differenti-
ated control at 9 and 15 days. In addition, the levels of
CTGF in p55-gag treated cells was lower at day 6 than
those in untreated differentiating cell. Taken together
these results suggest that p55-gag interferes with the oste-
ogenic function by inducing changes in the levels of key
signalling molecules. Previous studies by our group
showed that p55-gag could impair the function of mature
Effect of HIV1 proteins on transcription factor activity in non  differentiating MSCs Figure 6
Effect of HIV1 proteins on transcription factor activ-
ity in non differentiating MSCs. MSCs were cultured in 
the presence of 100 ng/ml HIV p55-gag and REV for 7 days. 
Untreated cells were included as controls. Cells were har-
vested and nuclear extracts were prepared and analysed for 
RUNX-2 and PPARγ activity. Data expressed as percentage 
of untreated control ± SEM. All data is the mean of several 
independent experiments. (Significance determined at; *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.005.)
Summary of findings for differentiation experiments Figure 7
Summary of findings for differentiation experiments.BMC Musculoskeletal Disorders 2008, 9:33 http://www.biomedcentral.com/1471-2474/9/33
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osteoblasts, and alter the levels of RUNX-2, and BMP-2 to
a similar degree [24]. Our findings with regard to differen-
tiating MSCs clearly build on this (Fig. 7).
In contrast to the anti-osteogenic role played by p55-gag,
REV clearly has a pro-osteogenic effect. Not only was the
magnitude of several of the examined parameters (such as
calcium deposition and RUNX-2 activity) greater over
many of the time-points examined, the osteogenic process
seems to be accelerated, with earlier increases in the levels
of CTGF and BMP-2 observed at day 3. The levels of
RUNX-2 and CTGF were also higher at day 15 than those
of untreated, differentiated cells; this may be indicative of
further osteogenesis occurring, or the beginning of a proc-
ess of differentiation into another cell type such as
chondrocytes (Fig. 7) [22,30].
Having demonstrated that HIV proteins interfere with the
normal process of MSC osteogenic differentiation; we
studied the possibility that HIV proteins alone could
induce some degree of differentiation. We treated MSCs
with p55-gag and REV for 7 days (an intermediate time
point at which time we proposed any significant molecu-
lar/functional shift towards an osteogenic/adipogenic
phenotype would be evident) and examined the func-
tional markers of osteoblastogenesis (ALP and calcium
deposition), and adipogenesis (lipid accumulation). We
also examined the activity levels of the key transcription
factors RUNX-2 and PPARγ. At a functional level both pro-
teins (and REV in particular) were seen to increase osteo-
genic markers, and decrease lipid staining; findings which
would seem to indicate that they are driving a pro-osteo-
genic phenotype. However, at the transcription factor
level, although REV significantly increased RUNX-2 activ-
ity, it also increased the levels of the pro-adipogenic
PPARγ (as did p55-gag, although it was not significant [p
= 0.097]). As the actions of PPARγ and RUNX-2 in MSC
differentiation are generally considered to oppose each
other [17], with, for example, suppression of PPARγ being
necessary for osteogenesis to occur [31], the results of
these experiments suggest that although the proteins may
disrupt MSC function and signalling to a certain degree, it
seems unlikely that they in and of themselves are capable
of inducing differentiation. It may be interesting to ascer-
tain if HIV proteins alter other MSC functions, such as
proliferation and migration. However we feel such exper-
iments are beyond the scope of the current study.
The findings of our study suggests that HIV proteins may
regulate the production of osteoblasts from mesenchymal
progenitors, through interfering with the process of oste-
ogenesis. In vivo, this alteration in functional osteoblast
numbers may drive decreased bone mineral density seen
in HIV patients. Previous studies have demonstrated that
exposure of MSC to HIV-1 virus in vitro can impair the clo-
nogenic potential of MSCs in a TAT protein dependent
manner [32], and our findings fit into a general hypothe-
sis of a HIV mediated disregulation of MSC function. The
exact contribution of virus and treatment to the process of
loss of BMD observed in HIV1 infected patients remains
unclear. Although successful HAART can reduce serum
levels of virus to almost undetectable levels, residual
latent infection in various tissue types can remain [33]. It
is also plausible that exposure to HIV1 proteins early in
infection or infection of MSC/OB cell types 'prime' these
cells to the inhibitory effects of HAART. Furthermore,
MSC/OB cell types interact with numerous other cell types
throughout their development, and the disruption of
these interactions, rather than disruption of MSC/OB
themselves, may be a contributory factor in the clinically
observed losses in bone mass. The possibility that both
MSCs and hematopoietic cell types can be affected by
secreted inhibitory factors from HIV1 infected stroma has
been considered, and it has been demonstrated in long
term tissue culture models that that altered support of
hematopoietic stem cells occurred only when the stromal
layer was susceptible to infection with HIV1 [33,34]. It is
worth noting that altough the treatment of cells with
exogenously added HIV proteins is a useful model it is not
ideal. In the future either experiments involving a combi-
nation of intercellular expression of certain proteins with
extracellular treatment of others, or attempting to infect
cultured MSCs with live HIV virus (possibly using meth-
odologies similar to that used by Wang et al. [32]), are
likely areas of future study as we attempt to extend this
hypothesis.
Conclusion
In conclusion, our findings suggest that HIV p55-gag and
REV alter the degree of osteogenesis in differentiating
MSCs by perturbing the timing and magnitude of impor-
tant osteogenic signals and processes. These data lend fur-
ther weight to the hypothesis that HIV infection drives
alterations in bone phenotype and provide a potential
mechanism for the evolution of this complication of
HIV1 infection.
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